Menu Icon Search

Investigating the ability of biomarkers to reduce uncertainty and misdiagnosis by people with dementia and other neurodegenerative disorders

September 28, 2021

The goal of The Markers in Neuropsychiatric Disorders (MiND) Study is to lead to a routine, clinically available blood test that will improve outcomes for people with cognitive, psychiatric and/or neurological symptoms, their families and carers, GPs, specialists, and healthcare systems.

The MiND Study is investigating the ability of biomarkers such as neurofilament light chain (NfL, a marker of neuronal injury), to reduce the years of uncertainty and misdiagnosis faced by many people with neurodegenerative disorders (especially younger-onset dementia). Research to date has shown promising results: a high NfL level can distinguish dementia from primary psychiatric and non-neurodegenerative disorders, with very high accuracy.

This research is led by Professor Dennis Velakoulis, Neuropsychiatrist and Director of Neuropsychiatry at The Royal Melbourne Hospital, and Dr Dhamidhu Eratne, Neuropsychiatrist and PhD Student, working with a growing list of high-profile national and international collaborators.

The study is welcoming referrals from general practitioners for patients aged 40–80, with recent (within five years) cognitive, psychiatric, and/or neurological symptoms. Eligibility criteria is available online. All that’s needed is a 2-minute online referral form. The study team will take it from there, managing all aspects of patient recruitment. The main requirement for patients is also minimal: a simple blood test, which can be done close to home.

The MiND Study has the potential to make a significant difference to the lives of many patients. You can hear some of the patient stories here.

For more information about the study, or to get in touch, please visit the MiND study website, or email